Advertisement
INFU vs IRMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INFU is a Buy and IRMD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INFU’s FA Score shows that 0 FA rating(s) are green whileIRMD’s FA Score has 2 green FA rating(s).
- INFU’s FA Score: 0 green, 5 red.
- IRMD’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INFU’s TA Score shows that 5 TA indicator(s) are bullish while IRMD’s TA Score has 4 bullish TA indicator(s).
- INFU’s TA Score: 5 bullish, 4 bearish.
- IRMD’s TA Score: 4 bullish, 4 bearish.
Price Growth
INFU (@Pharmaceuticals: Other) experienced а +3.40% price change this week, while IRMD (@Medical/Nursing Services) price change was -0.35% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.13%. For the same industry, the average monthly price growth was -3.06%, and the average quarterly price growth was +8.48%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.97%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +8.73%.
Reported Earning Dates
INFU is expected to report earnings on Nov 11, 2025.
IRMD is expected to report earnings on Oct 31, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-1.13% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.97% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| INFU | IRMD | INFU / IRMD | |
| Capitalization | 211M | 894M | 24% |
| EBITDA | 23.5M | 24.6M | 96% |
| Gain YTD | 22.367 | 28.865 | 77% |
| P/E Ratio | 43.08 | 43.65 | 99% |
| Revenue | 140M | 77.6M | 180% |
| Total Cash | 720K | 53M | 1% |
| Total Debt | 30.5M | 0 | - |
INFU | IRMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 21 | |
SMR RATING 1..100 | 73 | 40 | |
PRICE GROWTH RATING 1..100 | 38 | 45 | |
P/E GROWTH RATING 1..100 | 100 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRMD's Valuation (55) in the Medical Specialties industry is in the same range as INFU (72). This means that IRMD’s stock grew similarly to INFU’s over the last 12 months.
IRMD's Profit vs Risk Rating (21) in the Medical Specialties industry is significantly better than the same rating for INFU (100). This means that IRMD’s stock grew significantly faster than INFU’s over the last 12 months.
IRMD's SMR Rating (40) in the Medical Specialties industry is somewhat better than the same rating for INFU (73). This means that IRMD’s stock grew somewhat faster than INFU’s over the last 12 months.
INFU's Price Growth Rating (38) in the Medical Specialties industry is in the same range as IRMD (45). This means that INFU’s stock grew similarly to IRMD’s over the last 12 months.
IRMD's P/E Growth Rating (22) in the Medical Specialties industry is significantly better than the same rating for INFU (100). This means that IRMD’s stock grew significantly faster than INFU’s over the last 12 months.
| INFU | IRMD | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 80% |
| Stochastic ODDS (%) | 3 days ago 65% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 60% |
| MACD ODDS (%) | 3 days ago 78% | 3 days ago 64% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 58% |
| TrendMonth ODDS (%) | 3 days ago 75% | 3 days ago 64% |
| Advances ODDS (%) | 20 days ago 70% | 6 days ago 74% |
| Declines ODDS (%) | 12 days ago 78% | 4 days ago 55% |
| BollingerBands ODDS (%) | 3 days ago 82% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 76% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| LSHEX | 29.54 | 0.69 | +2.39% |
| Kinetics Spin-Off and Corp Rest No Load | |||
| BSCRX | 18.41 | 0.31 | +1.71% |
| Brandes Small Cap Value R6 | |||
| DSMZX | 10.54 | 0.12 | +1.15% |
| Destinations Small-Mid Cap Equity Z | |||
| AMGIX | 39.71 | 0.38 | +0.97% |
| American Century Discplnd Cor Val I | |||
| ILGRX | 43.56 | 0.21 | +0.48% |
| Macquarie Large Cap Growth Fund R6 | |||
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with QDEL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then QDEL could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | +2.58% | ||
| QDEL - INFU | 38% Loosely correlated | +6.76% | ||
| TMCI - INFU | 37% Loosely correlated | -0.30% | ||
| RDNT - INFU | 36% Loosely correlated | +1.05% | ||
| IRMD - INFU | 35% Loosely correlated | +2.51% | ||
| CERS - INFU | 34% Loosely correlated | -4.64% | ||
More | ||||
IRMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, IRMD has been loosely correlated with HBIO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if IRMD jumps, then HBIO could also see price increases.
| Ticker / NAME | Correlation To IRMD | 1D Price Change % | ||
|---|---|---|---|---|
| IRMD | 100% | +2.51% | ||
| HBIO - IRMD | 51% Loosely correlated | +1.07% | ||
| TWST - IRMD | 44% Loosely correlated | +0.60% | ||
| ICUI - IRMD | 43% Loosely correlated | +0.47% | ||
| ZIMV - IRMD | 43% Loosely correlated | N/A | ||
| ATRC - IRMD | 42% Loosely correlated | +0.49% | ||
More | ||||